- Contact Us Now: (202) 589-1834 Tap Here to Call Us
FTC Secures Preliminary Injunction Blocking Edwards Lifesciences’ Acquisition of JenaValve
On January 9, 2026, after a six-day trial, the U.S. District Court for the District of Columbia granted the Federal Trade Commission’s request for a preliminary injunction temporarily preventing Edwards Lifesciences Corp. from completing its proposed $945 million acquisition of JenaValve Technology, Inc. In response, Edwards announced that it would no longer pursue the acquisition. The outcome halted a transaction that the FTC alleged would have eliminated competition in the U.S. market for transcatheter aortic valve replacement devices used to treat aortic regurgitation (TAVR-AR devices).
The Transaction and Competitive Concerns
Edwards is a major manufacturer of cardiac medical devices. In 2024, it entered agreements to acquire both JenaValve and JC Medical—the two leading companies developing TAVR-AR devices and the only two with ongoing clinical trials in the United States for such products. Edwards completed its acquisition of JC Medical in July 2024. The proposed combination with JenaValve would have brought the only two remaining developers of these devices under common ownership.
The FTC challenged the deal in August 2025, alleging that the acquisition would substantially lessen competition in the U.S. market for TAVR-AR devices. The agency argued that the transaction would reduce innovation, diminish product quality, and potentially increase prices for patients needing treatment for aortic regurgitation, a potentially fatal heart condition. The court accepted a relevant market defined around the research, development, and commercialization of these pre-commercial devices, even though no TAVR-AR product had yet received FDA clearance for commercial sale in the United States.
Court Ruling and Parties’ Responses
Judge Rudolph Contreras granted the preliminary injunction after the evidentiary hearing. Bureau of Competition Director Daniel Guarnera called the decision “a major victory for the Trump-Vance FTC, American patients, and U.S. healthcare innovation,” stating that it preserves the head-to-head competition between Edwards and JenaValve that has expanded treatment options for patients with potentially fatal heart conditions. He emphasized that Americans benefit when companies compete to create new and lifesaving innovations, and that the FTC will continue to enforce the antitrust laws to protect consumers through lower costs, higher quality, and more innovation.
Edwards stated that it disagreed with the court’s decision and believed the acquisition would have been in the best interest of a large and underserved patient population. The company announced it would not proceed with the transaction and revised its full-year 2026 adjusted earnings-per-share guidance upward. The FTC later dismissed its related administrative complaint once the deal was abandoned.
Implications
The Edwards-JenaValve case is notable because it involved products still in clinical development rather than commercially marketed devices. The court’s acceptance of a market for the research, development, and commercialization of TAVR-AR devices confirms that antitrust enforcers can scrutinize combinations of close rivals in the innovation pipeline when those rivals are the only ones pursuing a particular therapy. The preliminary-injunction victory, followed by the parties’ abandonment of the deal, prevented the consolidation of the only two active U.S. clinical-trial programs for these devices.
For medical-device companies evaluating acquisitions of development-stage competitors, the outcome underscores that strong evidence of head-to-head innovation rivalry can support a successful challenge even before products reach the market. The FTC framed the result as protecting competition that drives new treatments for serious conditions, and the case adds to a series of recent healthcare-related enforcement actions under the current Commission.
Andre Barlow
abarlow@dbmlawgroup.com






